Benitec's BB-301 Hits 100% Response Rate; High Dose Beats Low Dose at Month 3
BNTC is trading near its 52-week low of $8 (10% above the low).
Summary
Benitec reported positive interim Phase 1b/2a results for high dose BB-301, with all nine patients treated across both cohorts responding to therapy and the high dose outperforming the low dose on swallowing measures at three months. No Serious Adverse Events have occurred, and the company is guiding toward a pivotal study in mid-2027.
Key Events · Product Development and Regulatory · BNTC
-
High-Dose BB-301 Interim Data Positive
Interim Phase 1b/2a results for high dose BB-301 showed all three Cohort 2 patients are formal responders, with 12-month follow-up complete for all six low-dose Cohort 1 patients.
-
High Dose Outperforms at Month 3
At the 3-month post-treatment time point, 100% of Cohort 2 versus 67% of Cohort 1 met response criteria for improved throat emptying, and 67% versus 17% met criteria on the Cold-Water Timed Drinking Test; total SSQ response was 100% in both cohorts.
-
Clean Safety Profile So Far
No Serious Adverse Events have been reported in any patient treated with BB-301 to date.
-
Pivotal Study Guided to Mid-2027
Management continues to target initiation of the BB-301 pivotal study in mid-2027, following FDA feedback on study design disclosed earlier in October 2026.
Analysis · BNTC · Life Sciences
This clinical data readout underpins Benitec's entire valuation, as BB-301 is the lead and only clinical program. All nine patients treated across both dose cohorts are formal responders, and the high dose showed a cleaner efficacy profile at the three-month mark: 100% versus 67% on throat emptying and 67% versus 17% on the Cold-Water Timed Drinking Test. No Serious Adverse Events have been reported in any treated patient. The company now points to a pivotal study in mid-2027, so the next hard checkpoint is the FDA-aligned pivotal design and its start date rather than any near-term data. With roughly $180M in cash as of the FY2026 10-K, funding the pivotal program is not the immediate constraint; execution and regulatory alignment are.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 36.5% of the 953 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BNTC was trading at $8.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $302.8M. The 52-week trading range was $8.00 to $16.76. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.